Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
Will Takeda’s Zasocitinib Redefine Oral Psoriasis Treatment?
Research & Development Will Takeda’s Zasocitinib Redefine Oral Psoriasis Treatment?

The landscape of autoimmune treatment is currently undergoing a seismic shift as high-potency oral medications begin to rival the long-standing dominance of injectable biologic therapies. Takeda Pharmaceutical Company recently demonstrated that its experimental drug, zasocitinib, could

GSK Pursues Quantum Resilience and Pharmaceutical Innovation
Management & Regulatory GSK Pursues Quantum Resilience and Pharmaceutical Innovation

The pharmaceutical industry stands at a precarious crossroads where the very technologies promising to cure incurable diseases also threaten to dismantle the digital foundations of intellectual property protection. GlaxoSmithKline currently finds itself navigating this complex landscape by

Trend Analysis: AI Digital Twins in Rehabilitation
Tech & Innovation Trend Analysis: AI Digital Twins in Rehabilitation

The intricate dance between neural pathways and linguistic expression often collapses after a neurological event, leaving millions in a silent struggle that traditional medical practices have historically struggled to quantify with precision. With approximately 2 million Americans currently living

How Will AI and Data Drive the Future of Clinical Analytics?
Management & Regulatory How Will AI and Data Drive the Future of Clinical Analytics?

The global healthcare landscape is currently undergoing a massive transformation as medical institutions move away from traditional, reactive care toward a proactive, data-driven approach that anticipates patient needs before they become critical. This transition relies heavily on a new generation

Merck and Gilead Face Oncology Setback and HIV Breakthrough
Research & Development Merck and Gilead Face Oncology Setback and HIV Breakthrough

The pharmaceutical landscape often operates on a razor's edge where multi-billion dollar investments can be validated or neutralized by a single data readout from a Phase 3 clinical trial. Merck and Gilead Sciences currently find themselves navigating this volatility as they balance the demands of

Breakthrough Therapy Shrinks Advanced Head and Neck Tumors
Research & Development Breakthrough Therapy Shrinks Advanced Head and Neck Tumors

The clinical landscape for treating advanced head and neck cancers has undergone a radical transformation following the publication of results from the Phase Ib/II OrigAMI-4 clinical trial, which offers a lifeline to those facing terminal diagnoses. This pivotal study, spearheaded by investigators

Is TIGIT the Key to Overcoming Immunotherapy Resistance?
Research & Development Is TIGIT the Key to Overcoming Immunotherapy Resistance?

Ivan Kairatov brings a wealth of experience from the front lines of biopharma research and development, specializing in the technological shifts that define modern oncology. As traditional therapies hit the wall of drug resistance, Ivan’s insights into T-cell immunoglobulin and immunoreceptor

WWOX Gene Replacement Therapy – Review
Research & Development WWOX Gene Replacement Therapy – Review

The landscape of neuro-pediatrics shifted significantly when medical professionals successfully administered a groundbreaking gene replacement therapy to an infant suffering from a rare, terminal genetic condition. This procedure, performed at the Schneider Children's Medical Center, targeted

Advanced Mixing Solves High-Viscosity Bioprocess Challenges
Biotech & Bioprocessing Advanced Mixing Solves High-Viscosity Bioprocess Challenges

The biopharmaceutical industry is currently witnessing a transformative shift toward extreme process intensification, where the drive for higher volumetric productivity is pushing cellular densities to unprecedented levels. In the quest to minimize the physical footprint of manufacturing facilities

Levin Center Pioneers In-House 3D-Printed Medical Implants
Management & Regulatory Levin Center Pioneers In-House 3D-Printed Medical Implants

The precision of modern surgical intervention has reached a point where the traditional "one size fits all" approach to medical implants is no longer a viable standard for high-stakes procedures. At the Levin Center for Surgical Innovation and 3D Printing, located within the Ichilov Medical Center,

Loading
Latest Articles

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later